Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125230481 | 12523048 | 1 | I | 20160525 | 20160627 | 20160701 | 20160701 | EXP | PHHY2016FR089343 | NOVARTIS | 80.97 | YR | F | Y | 0.00000 | 20160702 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125230481 | 12523048 | 1 | PS | AFINITOR | EVEROLIMUS | 1 | Oral | UNK | Y | 22334 | |||||||||
| 125230481 | 12523048 | 2 | SS | AROMASIN | EXEMESTANE | 1 | Oral | 25 MG, QD | 125 | MG | Y | 0 | 25 | MG | QD | ||||
| 125230481 | 12523048 | 3 | C | SKENAN | MORPHINE SULFATE | 1 | Unknown | 10 MG, BID | U | 0 | 10 | MG | BID | ||||||
| 125230481 | 12523048 | 4 | C | LEVOTHYROX | LEVOTHYROXINE | 1 | Unknown | 75 UG, UNK | U | 0 | 75 | UG | |||||||
| 125230481 | 12523048 | 5 | C | SEROPRAM | CITALOPRAM HYDROBROMIDE | 1 | Unknown | 30 MG, QD | U | 0 | 30 | MG | QD | ||||||
| 125230481 | 12523048 | 6 | C | LASILIX | FUROSEMIDE | 1 | Unknown | 40 MG, QD | U | 0 | 40 | MG | QD | ||||||
| 125230481 | 12523048 | 7 | C | MOVICOL | POLYETHYLENE GLYCOL 3350POTASSIUM CHLORIDESODIUM BICARBONATESODIUM CHLORIDE | 1 | Unknown | U | 0 | ||||||||||
| 125230481 | 12523048 | 8 | C | SOLUPRED | PREDNISOLONE | 1 | Unknown | 60 MG, QD | U | 0 | 60 | MG | QD | ||||||
| 125230481 | 12523048 | 9 | C | LYTOS | CLODRONATE DISODIUM | 1 | Unknown | 520 MG, (IN THE EVENING) | U | 0 | 520 | MG | |||||||
| 125230481 | 12523048 | 10 | C | LOVENOX | ENOXAPARIN SODIUM | 1 | Unknown | 0.4 OT, UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125230481 | 12523048 | 1 | Breast cancer metastatic |
| 125230481 | 12523048 | 2 | Breast cancer metastatic |
| 125230481 | 12523048 | 3 | Product used for unknown indication |
| 125230481 | 12523048 | 4 | Product used for unknown indication |
| 125230481 | 12523048 | 5 | Product used for unknown indication |
| 125230481 | 12523048 | 6 | Product used for unknown indication |
| 125230481 | 12523048 | 7 | Product used for unknown indication |
| 125230481 | 12523048 | 8 | Product used for unknown indication |
| 125230481 | 12523048 | 9 | Product used for unknown indication |
| 125230481 | 12523048 | 10 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125230481 | 12523048 | OT |
| 125230481 | 12523048 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125230481 | 12523048 | Aspartate aminotransferase increased | |
| 125230481 | 12523048 | Asthenia | |
| 125230481 | 12523048 | Blood creatine phosphokinase increased | |
| 125230481 | 12523048 | General physical health deterioration |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125230481 | 12523048 | 1 | 20160521 | 20160525 | 0 | |
| 125230481 | 12523048 | 2 | 20160521 | 20160525 | 0 |